Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
2008

Use of Heart Medications in Finnish Coronary Patients

Sample size: 2650 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kristiina Manderbacka, Ilmo Keskimäki, Antti Reunanen, Timo Klaukka

Primary Institution: National Research and Development Centre for Welfare and Health

Hypothesis

This study aimed to describe the use of antithrombotic drugs, beta-blockers, and statins among middle-aged Finnish coronary patients and to identify patient groups at risk of inadequate medication for secondary prevention of coronary heart disease.

Conclusion

The use of antithrombotic drugs and beta-blockers among Finnish coronary patients was generally appropriate, but statin use was notably low among men with low socioeconomic status.

Supporting Evidence

  • 82% of men and 81% of women used beta-blockers.
  • 95% of men and 89% of women used antithrombotic drugs.
  • 62% of men and 59% of women used statins.
  • Younger men and those from higher socioeconomic groups were more likely to use statins.

Takeaway

About half of the Finnish patients with heart disease are taking the right medications to prevent more heart problems, but some groups, like poorer men, are not getting enough of one important medicine.

Methodology

The study used one-year follow-up survey data from a random sample of coronary patients, with a response rate of 54%, and analyzed drug use using logistic regression.

Potential Biases

Potential biases include selective mortality and recall bias in reporting drug use.

Limitations

The study may have biases due to selective non-response and the inability to control for non-CHD related comorbidities.

Participant Demographics

The study included middle-aged Finnish coronary patients, with stratification by gender and socioeconomic status.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-9276-7-16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication